Global Hospital Acquired Infections Diagnostics Market Size Study, by Test (Molecular, Conventional), by Infection (UTI, Pneumonia), by Product (Consumables, Instruments), by Type (Blood Tests, Urinalysis), and Regional Forecasts 2022-2032

Description

The global hospital-acquired infections (HAI) diagnostics market was valued at approximately USD 4.23 billion in 2023 and is anticipated to expand at a CAGR of 1.49% over the forecast period 2024-2032. The alarming rise in the prevalence of HAIs, including surgical site infections, bloodstream infections, ventilator-associated pneumonia, and catheter-associated urinary tract infections, has propelled the demand for rapid and accurate diagnostic solutions. Hospitals, diagnostic laboratories, and healthcare facilities worldwide are increasingly adopting advanced molecular testing methods to curb infection outbreaks and improve patient safety.

The demand for early detection and effective containment of HAIs has intensified, given their impact on hospital mortality rates, prolonged hospital stays, and rising treatment costs. According to the World Health Organization (WHO), nearly 1 in 10 hospitalized patients worldwide is likely to contract an HAI, while the Centers for Disease Control and Prevention (CDC) states that 1 in 31 hospitalized patients in the U.S. acquires an HAI daily. The economic burden associated with HAIs, exceeding USD 28 billion annually in the U.S. alone, further underscores the need for advanced diagnostic tools. The growing threat of multidrug-resistant organisms (MDROs), including methicillin-resistant Staphylococcus aureus (MRSA) and Clostridioides difficile (C. difficile), is driving the adoption of molecular diagnostics such as Polymerase Chain Reaction (PCR)-based tests, enabling early detection and effective treatment strategies.

The conventional diagnostic methods segment held a dominant share of the market in 2023, owing to their established reliability and affordability. However, molecular diagnostics, with its ability to offer rapid pathogen detection, is expected to witness the fastest CAGR of 1.71% during the forecast period. Technological advancements such as real-time PCR, multiplex PCR, and next-generation sequencing (NGS) have significantly enhanced diagnostic accuracy and turnaround times, aiding infection control measures in hospitals and intensive care units (ICUs). For instance, in April 2023, Llusern Scientific introduced the Lodestar DX analyzer for rapid urinary tract infection (UTI) diagnostics, emphasizing the growing shift toward advanced molecular detection techniques.

Geographically, Europe dominated the global market in 2023, capturing the largest share due to stringent hospital infection control policies, extensive healthcare expenditure, and the presence of leading diagnostic manufacturers such as bioMerieux and QIAGEN. The Asia-Pacific region is projected to exhibit the fastest growth rate, driven by increasing awareness, rising healthcare investments, and an expanding geriatric population more susceptible to HAIs. Countries like China and India are implementing government-led infection monitoring programs to strengthen HIV, tuberculosis, and antibiotic resistance control measures, further driving market growth. Meanwhile, North America remains a strong contender, given its high prevalence of HAIs, well-established healthcare infrastructure, and ongoing R&D efforts in automated molecular diagnostic systems.

Major market players included in this report are:

Abbott
bioMerieux S.A.
Hoffmann-La Roche Ltd.
Siemens Healthcare Private Limited
Becton, Dickinson and Company (BD)
QIAGEN
Thermo Fisher Scientific Inc.
Meridian Bioscience, Inc.
Hologic, Inc.
Cepheid (Danaher Corporation)
Bio-Rad Laboratories, Inc.
Luminex Corporation
GenePOC Inc.
T2 Biosystems, Inc.
Accelerate Diagnostics, Inc.

The detailed segments and sub-segments of the market are explained below:

By Test:

Molecular
Conventional

By Infection:

Urinary Tract Infection (UTI)
Pneumonia
Surgical Site Infections
Bloodstream Infections
Others

By Product:

Consumables
Instruments

By Type:

Blood Tests
Urinalysis

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
Thailand
South Korea
Latin America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait

Years considered for the study are as follows:

Historical Year - 2022
Base Year - 2023
Forecast Period - 2024 to 2032

Key Takeaways:

Market estimates & forecasts from 2022 to 2032.
Detailed regional and segmental analysis.
Competitive landscape with insights into key players and strategic developments.
Investment opportunities, technological advancements, and regulatory frameworks shaping the industry.
Analysis of market demand-supply dynamics and consumer behavior trends.

Chapter 1. Global Hospital Acquired Infections Diagnostics Market Executive Summary

1.1. Global Hospital Acquired Infections Diagnostics Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Test
- 1.3.2. By Infection
- 1.3.3. By Product
- 1.3.4. By Type
1.4. Key Market Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Hospital Acquired Infections Diagnostics Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory Frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Hospital Acquired Infections Diagnostics Market Dynamics

3.1. Market Drivers
- 3.1.1. Increasing prevalence of HAIs and antimicrobial resistance
- 3.1.2. Advancements in molecular diagnostic technologies
- 3.1.3. Growing hospital infection control initiatives
3.2. Market Challenges
- 3.2.1. High costs associated with advanced diagnostic systems
- 3.2.2. Stringent regulatory approval processes
3.3. Market Opportunities
- 3.3.1. Emerging AI-powered diagnostic solutions
- 3.3.2. Expansion of healthcare infrastructure in developing economies
- 3.3.3. Increasing investments in R&D for rapid testing methods

Chapter 4. Global Hospital Acquired Infections Diagnostics Market Industry Analysis

4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's Five Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Test (2022-2032)

5.1. Segment Dashboard
5.2. Global Market: Test Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 5.2.1. Molecular Diagnostics
- 5.2.2. Conventional Diagnostics

Chapter 6. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Infection (2022-2032)

6.1. Segment Dashboard
6.2. Global Market: Infection Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 6.2.1. Urinary Tract Infection (UTI)
- 6.2.2. Pneumonia
- 6.2.3. Surgical Site Infections
- 6.2.4. Bloodstream Infections
- 6.2.5. Others

Chapter 7. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Product (2022-2032)

7.1. Segment Dashboard
7.2. Global Market: Product Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 7.2.1. Consumables
- 7.2.2. Instruments

Chapter 8. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Type (2022-2032)

8.1. Segment Dashboard
8.2. Global Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
- 8.2.1. Blood Tests
- 8.2.2. Urinalysis

Chapter 9. Global Hospital Acquired Infections Diagnostics Market Size & Forecasts by Region (2022-2032)

9.1. North America Hospital Acquired Infections Diagnostics Market
- 9.1.1. U.S.
  - 9.1.1.1. Test breakdown size & forecasts, 2022-2032
  - 9.1.1.2. Infection breakdown size & forecasts, 2022-2032
  - 9.1.1.3. Product breakdown size & forecasts, 2022-2032
  - 9.1.1.4. Type breakdown size & forecasts, 2022-2032
- 9.1.2. Canada
9.2. Europe Hospital Acquired Infections Diagnostics Market
- 9.2.1. U.K.
- 9.2.2. Germany
- 9.2.3. France
- 9.2.4. Spain
- 9.2.5. Italy
- 9.2.6. Rest of Europe
9.3. Asia-Pacific Hospital Acquired Infections Diagnostics Market
- 9.3.1. China
- 9.3.2. India
- 9.3.3. Japan
- 9.3.4. Australia
- 9.3.5. South Korea
- 9.3.6. Rest of Asia Pacific
9.4. Latin America Hospital Acquired Infections Diagnostics Market
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
9.5. Middle East & Africa Hospital Acquired Infections Diagnostics Market
- 9.5.1. Saudi Arabia
- 9.5.2. South Africa
- 9.5.3. Rest of Middle East & Africa

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
- 10.1.1. Abbott
- 10.1.2. bioMerieux S.A.
- 10.1.3. Hoffmann-La Roche Ltd.
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Abbott
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. bioMerieux S.A.
- 10.3.3. Hoffmann-La Roche Ltd.
- 10.3.4. Siemens Healthcare Private Limited
- 10.3.5. Becton, Dickinson and Company (BD)
- 10.3.6. QIAGEN
- 10.3.7. Thermo Fisher Scientific Inc.
- 10.3.8. Meridian Bioscience, Inc.
- 10.3.9. Hologic, Inc.
- 10.3.10. Cepheid (Danaher Corporation)

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes